Primary systemic therapy for operable breast cancer. 1991

E D Anderson, and A P Forrest, and R A Hawkins, and T J Anderson, and R C Leonard, and U Chetty
University Department of Surgery, Royal Infirmary, Edinburgh, UK.

Eighty-eight patients presenting with operable breast cancer of 4 cm or greater in diameter (T2, T3, N0, N1, M0) have received primary systemic therapy. Response was assessed following 12 weeks of systemic therapy by linear regression analysis of changes in tumour volume. Definitive locoregional surgery (mastectomy n = 82, wide local excision n = 6) was performed on completion of systemic therapy (3-6 months). Response was observed in 24 (39%) of the 61 patients who received endocrine therapy; all 24 had tumours with an oestrogen receptor (ER) concentration of greater than or equal to 20 fmol mb-1 cytosol protein. Cytotoxic therapy was reserved for patients with tumours of ER concentration less than 20 fmol mg-1 cytosol protein (n = 27) or when endocrine therapy had failed (n = 20). Response was observed in 34 patients (72%). The overall survival rate at 3 years was 86%, with 81% remaining free from local relapse. We propose that the treatment policy outlined in this paper should now be tested against orthodox management by controlled randomised trial.

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010052 Ovariectomy The surgical removal of one or both ovaries. Castration, Female,Oophorectomy,Bilateral Ovariectomy,Bilateral Ovariectomies,Castrations, Female,Female Castration,Female Castrations,Oophorectomies,Ovariectomies,Ovariectomies, Bilateral,Ovariectomy, Bilateral
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002064 Buserelin A potent synthetic analog of GONADOTROPIN-RELEASING HORMONE with D-serine substitution at residue 6, glycine10 deletion, and other modifications. Bigonist,Buserelin Acetate,HOE-766,Profact,Receptal,Suprecur,Suprefact,Tiloryth,Acetate, Buserelin,HOE 766,HOE766
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

E D Anderson, and A P Forrest, and R A Hawkins, and T J Anderson, and R C Leonard, and U Chetty
April 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E D Anderson, and A P Forrest, and R A Hawkins, and T J Anderson, and R C Leonard, and U Chetty
June 2007, Nihon rinsho. Japanese journal of clinical medicine,
E D Anderson, and A P Forrest, and R A Hawkins, and T J Anderson, and R C Leonard, and U Chetty
April 2007, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland,
E D Anderson, and A P Forrest, and R A Hawkins, and T J Anderson, and R C Leonard, and U Chetty
April 1991, British medical bulletin,
E D Anderson, and A P Forrest, and R A Hawkins, and T J Anderson, and R C Leonard, and U Chetty
November 1989, European journal of cancer & clinical oncology,
E D Anderson, and A P Forrest, and R A Hawkins, and T J Anderson, and R C Leonard, and U Chetty
January 1975, Connecticut medicine,
E D Anderson, and A P Forrest, and R A Hawkins, and T J Anderson, and R C Leonard, and U Chetty
April 2007, Cancer letters,
E D Anderson, and A P Forrest, and R A Hawkins, and T J Anderson, and R C Leonard, and U Chetty
November 2008, Nederlands tijdschrift voor geneeskunde,
E D Anderson, and A P Forrest, and R A Hawkins, and T J Anderson, and R C Leonard, and U Chetty
February 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E D Anderson, and A P Forrest, and R A Hawkins, and T J Anderson, and R C Leonard, and U Chetty
May 2006, Annals of oncology : official journal of the European Society for Medical Oncology,
Copied contents to your clipboard!